Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

This study is ongoing, but not recruiting participants.
Deutsche Krebshilfe e.V., Bonn (Germany)
Information provided by (Responsible Party):
Martin Fassnacht, University of Wuerzburg Identifier:
First received: April 4, 2007
Last updated: September 9, 2015
Last verified: September 2015
Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.

Condition Phase
Adrenocortical Carcinoma
Cushing's Syndrome
Phase 0

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Target Follow-Up Duration: 2 Years
Official Title: Präklinische Studie Zur Etablierung Einer Immuntherapie für Das Nebennierenrindenkarzinom - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

Resource links provided by NLM:

Further study details as provided by University of Wuerzburg:

Primary Outcome Measures:
  • To find reasonable antigens for a vaccination therapy in ACC [ Time Frame: day of blood sampling ] [ Designated as safety issue: No ]
  • To investigate the role of tumor-induced suppression in ACC [ Time Frame: NA, in vitro study ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
whole blood for monocytes isolation serum urine

Enrollment: 70
Study Start Date: September 2005
Estimated Study Completion Date: December 2016
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Adrenocortical carcinoma

Inclusion Criteria:

  • patients with histological proven adrenocortical carcinoma
  • healthy persons as control group
  • Life expectancy > 6 months

Exclusion Criteria:

  • autoimmune diseases
  • severe clinical condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00457587

Dept. of Medicine I, University of Wuerzburg
Wuerzburg, Germany, 97080
Sponsors and Collaborators
University of Wuerzburg
Deutsche Krebshilfe e.V., Bonn (Germany)
Principal Investigator: Martin Fassnacht, MD University of Wuerzburg
  More Information

Responsible Party: Martin Fassnacht, Professor for Internal Medicine and Endocrinology, University of Wuerzburg Identifier: NCT00457587     History of Changes
Other Study ID Numbers: Wue-Immuno-ACC-83/05 
Study First Received: April 4, 2007
Last Updated: September 9, 2015
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Adrenocortical Carcinoma
Cushing Syndrome
Adrenal Cortex Diseases
Adrenal Cortex Neoplasms
Adrenal Gland Diseases
Adrenal Gland Neoplasms
Adrenocortical Hyperfunction
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial processed this record on May 24, 2016